GSK Wins Regulatory Nod for Bronchial Asthma Treatment in Japan

MT Newswires · 4d ago
02:19 AM EST, 01/06/2026 (MT Newswires) -- British drugmaker GSK (GSK.L) secured regulatory approval for its bronchial asthma and chronic rhinosinusitis with nasal polyps treatment Exdensur, or depemokimab, in Japan. The approval from Japan's Ministry of Health, Labour and Welfare was supported by data from two phase 3 trials, which showed "sustained efficacy" versus placebo, following twice-yearly doses of depemokimab, alongside standard of care, according to a Tuesday filing. The Swift-1 and Swift-2 trials demonstrated significant reductions in asthma exacerbations, while the Anchor-1 and Anchor-2 trials showed improvements in nasal polyp size and nasal obstruction. The drug has already been approved in the US and the UK and is under regulatory review in other markets, including China.